Insider Transaction Report for Kazam Joshua A

On June 18, 2026, Kazam Joshua A, a director at Allogene Therapeutics, Inc. (ALLO), reported a series of transactions involving Common Stock and Restricted Stock Units (RSUs). Kazam acquired 47,700 shares of Common Stock via a Form 4 filing (Transaction Code M, Acquired Code A), with a post-transaction share count of 398,463. Concurrently, Kazam was involved in two RSU transactions: a disposal of 47,700 RSUs (Transaction Code M, Disposed Code D) and an award of 95,400 RSUs (Transaction Code A, Acquired Code A). These RSUs are contingent rights to receive shares of common stock or cash in lieu thereof. The RSUs awarded are subject to vesting over a one-year period in two semi-annual installments, contingent upon continued service. All transactions were reported with a price of $0.00.